Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

The U.S. has been adept at inventing The Next Big Thing but sometimes stumbles when it comes to exploiting it. From cars to ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

There are more foreign companies paying to license technology from the U.S. National Institutes of Health than companies ...

The China fight is on. Last week, the House of Representatives stepped up to the Herculean task of passing 25 bills targeting ...

The good news is that if you're willing to put in a bit of effort, it's very possible to improve on your process to secure ...

A rare-disease federal incentive program critical to biotech R&D is in jeopardy, writes Leslie Williams, president and CEO of ...

European equities traded in the US as American depositary receipts were falling on Friday morning, down 1.5% to 1,436.90 on the S&P Europe Select ADR Index. From continental Europe, the gainers were ...

The interest rate cut expected this week has a potential double impact of opening financial options to emerging growth ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today ...